VSTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Verastem, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$8.62−0.03 (-0.35%)
Close on Oct 19, 2026
- Market cap
- $863.00M
- P/E (TTM)
- –
- Dividend yield
- –
Verastem, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q1 24 | Q4 22 | Q3 22 | Q2 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $25.08M | $18.67M | $17.54M | $11.24M | $2.14M | – | – | – | – | – | – | – | 62.6% | +1073.5% |
| Sale of COPIKTRA license and related assets | $15.00M | – | – | – | – | – | $0 | – | $10.00M | $0 | $0 | $0 | 37.4% | – |
By region
From the segment and revenue-disaggregation notes of Verastem's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.